Is the prognostic nutritional index a prognostic and predictive factor in metastatic non-small cell lung cancer patients treated with first-line chemotherapy?

Bozkaya, Yakup; Köstek, Osman; Sakin, Abdullah; Özyükseler, Deniz Tataroğlu; Sakalar, Teoman; Çil, İbrahim

doi:10.1007/s00520-019-05055-x

Cited by 18 publications

(16 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yakup et al analysis of NSCLC showed that there were marked distinction in clinical characteristics distribution, overall survival and progression free survival between the high-OPNI group and the low-OPNI group. [ 31 ] Similarly, in our further analysis of the relationship between OPNI and clinicopathological features, there were differences in treatment, postoperative therapy, AST, ALBI grade, NLR and PLR between 2 groups.…”

Section: Discussionmentioning

confidence: 82%

“…In the analysis of OPNI in patients with colorectal cancer and malignant pleural mesothelioma, some scholars found that the prognosis of patients with OPNI lower than cut-off value was signi cantly worse than that of patients with OPNI higher than cut-off value (26)(27). Yakup Bozkaya et al 's analysis of NSCLC showed that there were signi cant differences in clinical characteristics distribution, overall survival and progression free survival between the high-OPNI group and the low-OPNI group (28).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic value of inflammatory and nutritional markers for hepatocellular carcinoma

Yuan

Zhang³

et al. 2021

Medicine

View full text Add to dashboard Cite

Background: It is well known that the prognosis of cancer patients after tumor resection is closely related to the patient's autoimmune ability and nutritional status. A large number of studies have shown that the neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and Onodera's prognostic nutritional index (OPNI) are signi cantly correlated with the prognosis of various tumors. In this study, we analyzed the prognostic value of NLR, PLR and OPNI for hepatocellular carcinoma (HCC) for the rst time.Patients and Methods: Data of hepatocellular carcinoma patients undergoing hepatectomy in Changzhi People's Hospital (Changzhi, China) from 2011 to 2017 were retrospectively analyzed. A total of 286 patients with hepatocellular carcinoma were included in the analysis. The Optimum cut-off values of OPNI, NLR and PLR were determined by using the X-tile program. The overall survival (OS) was analyzed by Kaplan-Meier method and veri ed by log-rank test. Multivariate analysis was performed using Cox Proportional Hazard Regression model to determine independent prognostic indicators for HCC.Results: Univariate and multivariate analysis showed that OPNI (p<0.001), Treatment (Surgery, p=0.04;Interventional therapy, p=0.002), Postoperative treatment (YES, p=0.004) and Stage can be used as independent prognostic maker for HCC. Comparing the P values and hazard ratios, we found out that the OPNI has greatest in uence on prognosis in these preoperative indexes. The optimal cut-off values of NLR, PLR and OPNI were 2.5, 133.3 and 39.5, respectively. Compared with the low OPNI group, the high OPNI group had a better prognosis. In the correlation analysis between OPNI and clinicopathological features, only Age and NLR showed statistical differences, while others did not.Conclusions: OPNI can be used as a simple and effective independent prognostic marker for hepatocellular carcinoma.

show abstract

Section: Discussionmentioning

confidence: 82%

Section: Discussionmentioning

confidence: 99%

Prognostic value of inflammatory and nutritional markers for hepatocellular carcinoma

Yuan

Zhang³

et al. 2021

Medicine

View full text Add to dashboard Cite

show abstract

“…Bozkaya et al. 18 reported that pretreatment PNI values were an independent prognostic factor for OS and PFS in patients with metastatic NSCLC treated with first-line chemotherapy. Current studies are investigating the use of the PNI as an indicator of clinical benefit in patients receiving chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Prognostic factors of patients with advanced lung cancer treated with anlotinib: a retrospective cohort study

et al. 2021

View full text Add to dashboard Cite

Objective Our study aimed to evaluate the main factors affecting the efficacy of anlotinib to determine the therapeutically dominant populations. Methods The medical records of patients with lung cancer who were treated with anlotinib from July 2018 to February 2020 at Renji Hospital, School of Medicine, Shanghai Jiaotong University were retrospectively reviewed. The optimal cutoff prognostic nutritional index (PNI) value for predicting efficacy was determined according to receiver operating characteristic curves. Progression-free survival (PFS) and overall survival (OS) were calculated and compared using the Kaplan–Meier method and log‐rank test. The prognostic values of each variable were evaluated with univariate and multivariate Cox proportional hazard regression analyses. Results The overall disease control rate of 44 patients with lung cancer was 93.2% (41/44). The median PFS was 5.0 months (95% [confidence interval] CI: 2.2–7.8), and the median OS was 6.5 months (95% CI: 3.6–9.3). The multivariate analysis results indicated that hand–foot syndrome and high PNI values were independent protective factors of PFS and OS. Conclusions Anlotinib was effective in treating locally advanced or advanced lung cancer. High pretreatment PNI scores and the presence of hand–foot syndrome after treatment were independent prognostic markers for favorable OS and PFS.

show abstract

“…In the past decades, commonly used hematological indicators have included serum biomarkers, popular tumor markers, and imaging examinations, which are widely used to predict and identify therapeutic effects but with low prognostic efficacy. Based on these routine tests, multiple studies have revealed that some indicators such as prognostic nutrition index (PNI), neutrophil-lymphocyte ratio (NLR), lymphocyte-tomonocyte ratio (LMR), and serum tumor markers could be predictive markers of clinical outcome in patients with lung cancer (5)(6)(7)(8)(9)(10). The synthesis of albumin and pre-albumin (PA) is inhibited by malnutrition and inflammation.…”

Section: Introductionmentioning

confidence: 99%

Monitoring early dynamic changes of plasma cell-free DNA and pretreatment pre-albumin to predict chemotherapy effectiveness and survival outcomes in advanced non-small cell lung cancer

Chen¹,

Shao²,

Zhang³

et al. 2022

Ann Transl Med

View full text Add to dashboard Cite

Background: This study aimed to determine whether plasma cell-free DNA (cfDNA) and pretreatment parameters provide useful therapeutic response and prognostic information for advanced non-small cell lung cancer (NSCLC) patients.Methods: A total of 114 patients with advanced NSCLC who underwent systemic chemotherapy were included in this study. Detection of plasma cfDNA concentration and blood parameters before and at the sixth week after treatment was performed. The prognostic value of cfDNA dynamic changes and laboratory parameters was determined via a receiver operating characteristic (ROC) curve, and then analyzed by comparing with the therapeutic efficacy and progression-free survival (PFS). Based on the ROC curve, it revealed a pretreatment pre-albumin (PA) concentration of 21.7 mg/dL was the cut-off value. The Cox proportional hazards regression model was used to evaluate the predictive factors for treatment response and PFS via univariate and multivariate analyses.Results: Patients with cfDNA reduction ≥20% at the sixth week after treatment reported a significantly better disease control rate (DCR) and prolonged PFS (median PFS: 10.0 vs. 4.0 months, P<0.001). The median PFS of low PA group (PA <21.7 mg/dL) was 6.0 months, while the median PFS of high PA group (PA ≥21.7 mg/dL) was 8.0 months. The combined assessment of cfDNA and pretreatment pre-albumin was associated with significantly better survival outcomes compared with the remaining population (P<0.001).Multivariate analysis for DCR indicated that cfDNA reduction ≥20% was an independent factor (OR =0.419, P=0.001). In addition, multivariate analysis identified 6 significant factors associated with PFS: cfDNA reduction of ≥20%, age <65 years, Eastern Cooperative Oncology Group (ECOG) score ≥2, driver gene mutation, chemotherapy combined regimen, and treatment response of complete response (CR) and partial response (PR). The nomogram could predict the 2-year PFS probability of advanced NSCLC patients after treatment, and the C-index was 0.817. Conclusions:Monitoring cfDNA changes and pretreatment pre-albumin level in advanced NSCLC patients receiving treatment is an accurate predictor of tumor response and PFS. Combined assessment of cfDNA and pretreatment pre-albumin is helpful for predicting survival outcomes. These findings may assist in identifying high-risk patients and guiding treatment strategies.

show abstract

Is the prognostic nutritional index a prognostic and predictive factor in metastatic non-small cell lung cancer patients treated with first-line chemotherapy?

Cited by 18 publications

References 30 publications

Prognostic value of inflammatory and nutritional markers for hepatocellular carcinoma

Prognostic value of inflammatory and nutritional markers for hepatocellular carcinoma

Prognostic factors of patients with advanced lung cancer treated with anlotinib: a retrospective cohort study

Monitoring early dynamic changes of plasma cell-free DNA and pretreatment pre-albumin to predict chemotherapy effectiveness and survival outcomes in advanced non-small cell lung cancer

Contact Info

Product

Resources

About